SAB Biotherapeutics Inc(SABS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:01 PM ET (Korea 11/7 06:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.69 | Insider Own | 10.4% | Shs Outstand | 91.1M | Perf Week | -9.55% |
| Market Cap | 0.28B | Forward P/E | - | EPS next Y | 34.21% | Insider Trans | - | Shs Float | 81.5M | Perf Month | 4.84% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.24 | Inst Own | 72.89% | Short Float | 5.89% | Perf Quarter | -19.84% |
| Income | -0.07B | P/S | - | EPS this Y | -40.8% | Inst Trans | 0.82% | Short Ratio | 8.98 | Perf Half Y | -26.28% |
| Sales | 0.00B | P/B | 1.31 | EPS next 5Y | 6.06% | ROA | -31.74% | Short Interest | 4.80M | Perf YTD | -18.98% |
| Book/sh | 2.31 | P/C | 2.65 | EPS past 3/5Y | 43.07% - | ROE | -35.38% | 52W High | -41.17% ($5.15) | Perf Year | -2.26% |
| Cash/sh | 1.14 | P/FCF | - | Sales past 3/5Y | - | ROIC | -30.89% | 52W Low | 24.18% ($2.44) | Perf 3Y | -69.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 60.7% | Gross Margin | - | Volatility(W/M) | 7.99% 8.22% | Perf 5Y | -96.37% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.28 | EPS Q/Q | -12.51% | Profit Margin | - | RSI (14) | 48.97 | Recom | 1.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.28 | Sales Q/Q | - | SMA20 | 3.57% ($2.93) | Beta | 0.77 | Target Price | $11.75 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/11/5 | SMA50 | -4.99% ($3.19) | Rel Volume | 0.56 | Prev Close | $2.94 |
| Employees | 86 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 12.6% - | SMA200 | -17.18% ($3.66) | Avg Volume(3M) | 0.53M | Price | $3.03 |
| IPO | 2021/2/9 | Option/Short | Yes/Yes | Trades | 1623 | Volume | 300,580 | Change | 3.06% |
SAB Biotherapeutics (SABS) is a US-based clinical-stage biotech company developing immunotherapies using human antibodies. Its lead candidate, SAB-142, is a disease-modifying human anti-thymocyte globulin (hATG) designed to slow the progression of Type 1 diabetes, representing a next-generation therapeutic mechanism in the autoimmune disease space.
Over the past 1 year, on the lower side
41% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
SABS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -40.8% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.4%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 72.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #274 of 597 in the industry
Based on market cap of $276M.
NAUT#270 Nautilus Biotechnology Inc $284M PER - 
FULC#271 Fulcrum Therapeutics Inc $282M PER - 
SPRY#272 ARS Pharmaceuticals Inc $277M PER - 
QTTB#273 Q32 Bio Inc $277M PER 2.8 SABS#274 SAB Biotherapeutics Inc $276M PER - 
FAQ
What kind of company is SABS?
SABS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SABS?
The market cap of SABS is approximately $276M, ranking 3,738 within its sector.
What is the 52-week high and low for SABS?
SABS has recorded a 52-week high of $5.15 and a low of $2.44.
